Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 737-755 , December 2006

Donor leukocyte infusions in myeloid malignancies: new strategies

  • David L. Porter, MD (Director, Allogeneic Stem Cell Transplantation, and Associate Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 215 662 2867; Fax: +1 215 662 4064.
  • Joseph H. Antin, MD (Chief, Stem Cell Transplantation Program, and Professor of Medicine)

References 

  1. Barnes D, Loutit J. Treatment of murine leukaemia with X-rays and homologous bone marrow. British Journal of Haematology. 1957;3:241–252
  2. Weiden P, Flournoy N, Donnall Thomas E, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. The New England Journal of Medicine. 1979;300:1068–1073
  3. Weiden P, Sullivan K, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. The New England Journal of Medicine. 1981;304:1529–1533
  4. Horowitz M, Gale R, Sondel P, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  5. Kolb H, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465
  6. Porter D, Roth M, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. The New England Journal of Medicine. 1994;330:100–106
  7. Drobyski W, Keever C, Roth M, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82(8):2310–2318
  8. Collins R, Shpilberg O, Drobyski W, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1997;15:433–444
  9. Alyea E, Soiffer R, Canning C, et al. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91:3671–3680
  10. Baurmann H, Nagel S, Binder T, et al. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. [comment] [erratum appears in Blood 1999 Mar 15;93(6):2141] Blood. 1998;92(10):3582–3590
  11. Verdonck LF, Petersen EJ, Lokhorst HM, et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplantation. 1998;22(11):1057–1063
  12. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Experimental Hematology. 1999;27(10):1477–1486
  13. Porter D, Connors J, VanDeerlin V, et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1999;17:1234–1243
  14. Bar B, Schattenberg A, Mensink E, et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1993;11(3):513–519
  15. Collins R, Rogers Z, Bennett M, et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplantation. 1992;10:391–395
  16. Cullis J, Jiang Y, Schwarer A, et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood. 1992;79:1379–1380
  17. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87:2195–2204
  18. Kolb H, Schattenberg A, Goldman J, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  19. Porter D, Collins R, Shpilberg O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 1999;5:253–261
  20. Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2000;96(8):2712–2716
  21. Gale R, Horowitz M, Ash R, et al. Identical-twin bone marrow transplants for leukemia. Annals of Internal Medicine. 1994;120:646–652
  22. Porter D, Roth M, Lee S, et al. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplantation. 1996;18:975–980
  23. Szer J, Grigg A, Phillipos G, et al. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplantation. 1993;11:109–111
  24. Singhal S, Powles R, Kulkarni S, et al. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leukemia & Lymphoma. 1999;32(5–6):505–512
  25. Choi SJ, Lee JH, Kim S, et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2004;18(11):1789–1797
  26. Berthou C, Leglise MC, Herry A, et al. Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1998;12(11):1676–1681
  27. Chong G, Byrnes G, Szer J, et al. Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplantation. 2000;26(9):1011–1015
  28. Levine J, Braun T, Penza S, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem cell transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2002;20:405–412
  29. Mackinnon S, Papadopoulos E, Carabasi M, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261–1268
  30. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000;95(1):67–71
  31. Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood. 2002;100(2):397–405
  32. Weiden P, Storb R, Tsoi M, et al. Infusion of donor lymphocytes into stable canine radiation chimeras: Implications for mechanism of transplantation tolerance. Journal of Immunology (Baltimore, Md.: 1950). 1978;116:1212–1219
  33. Kolb HJ, Gunther W, Schumm M, et al. Adoptive immunotherapy in canine chimeras. Transplantation. 1997;63(3):430–436
  34. Johnson B, Drobyski W, Truitt R. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplantation. 1993;11:329–336
  35. Porter D, Collins R, Hardy C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood. 2000;95:1214–1221
  36. Shiobara S, Nakao S, Ueda M, et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: indications and dose escalation. Therapeutic Apheresis: Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis. 2001;5(1):40–45
  37. Soiffer R, Alyea E, Hochberg E, et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2002;8:625
  38. Porter D, Antin J. Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions. In:  Winter J editors. Blood Stem Cell Transplantation. Norwell, MA: Kluwer Academic Publishers; 1997;p. 57–86
  39. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92(7):2303–2314
  40. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. [comment]. Blood. 1992;80(7):1838–1845
  41. Antin J, Ferrara J. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964–2968
  42. Akpek G, Boitnott JK, Lee LA, et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood. 2002;100(12):3903–3907
  43. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100(9):3108–3114
  44. Loren A, Luger S, Stadtmauer E, et al. Intensive graft-versus-host disease prophylaxis is required after unrelated donor non-myeloablative stem cell transplantation. Bone Marrow Transplantation. 2005;35:921–926
  45. Morris EC, Rebello P, Thomson KJ, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood. 2003;102(1):404–406
  46. Spitzer T, McAfee S, Sackstein R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2000;6:309–320
  47. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. [see comment]. Blood. 2004;103(4):1548–1556
  48. Tauro S, Craddock C, Peggs K, et al. Allogeneic Stem-Cell Transplantation Using a Reduced-Intensity Conditioning Regimen Has the Capacity to Produce Durable Remissions and Long-Term Disease-Free Survival in Patients With High-Risk Acute Myeloid Leukemia and Myelodysplasia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23:9387–9393
  49. Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2001;7(9):473–485
  50. Antin J. Stem Cell Transplantation-harnessing of graft-vs-malignancy. Current Opinion in Hematology. 2003;10:440–444
  51. Liebowitz D, Lee K, CH J. Costimulatory approaches to adoptive immunotherapy. Current Opinion in Oncology. 1998;10:533–541
  52. Levine BL, Bernstein WB, Connors M, et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. Journal of Immunology (Baltimore, Md.: 1950). 1997;159(12):5921–5930
  53. Laport GG, Levine BL, Stadtmauer EA, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood. 2003;102(6):2004–2013
  54. Porter DL, Levine B, Bunin N, et al. Enhancing graft-vs-tumor activity of donor lymphocyte infusions by ex-vivo expansion and activation with CD3/CD28 co-stimulation. Blood. 2006;107:1325–1331
  55. Cardoso AA, Seamon MJ, Afonso HM, et al. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood. 1997;90(2):549–561
  56. Kolb HJ, Schmid C, Barrett AJ, et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767–776
  57. Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004;103(1):353–359
  58. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. The Journal of Experimental Medicine. 2004;199(8):1133–1142
  59. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996;87(9):3587–3592
  60. Clark RE, Dodi IA, Hill SC, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 2001;98(10):2887–2893
  61. Voogt PJ, Goulmy E, Veenhof WF, et al. Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells. The Journal of Experimental Medicine. 1988;168(6):2337–2347
  62. Mackinnon S, Papadopoulos E, Carabasi M, et al. Adoptive Immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?. Bone Marrow Transplantation. 1995;15:591–594
  63. Mutis T, Verdijk R, Schrama E, et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93(7):2336–2341
  64. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(5):2742–2747
  65. Randolph SS, Gooley TA, Warren EH, et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103(1):347–352
  66. Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88(7):2450–2457
  67. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine. 2000;6(9):1018–1023
  68. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology. 2003;331–349
  69. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003;17(7):1301–1312
  70. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1999;13(3):393–399
  71. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95(5):1781–1787
  72. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 1999;94(4):1201–1208
  73. Montagna D, Maccario R, Montini E, et al. Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors. Experimental Hematology. 2003;31(11):1031–1038
  74. Schmid C, Lange C, Salat C, et al. Treatment of recurrent acute leukemia after marrow transplantation with donor cells and GM-CSF. Blood. 1999;94:668a
  75. Brouwer RE, van der Hoorn M, Kluin-Nelemans HC, et al. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. Human Immunology. 2000;61(6):565–574
  76. Choudhury BA, Liang JC, Thomas EK, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999;93(3):780–786
  77. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86:4337–4343
  78. Shimoni A, Gajewski J, Donato M, et al. Long-term follow-up of recipients of CD8 depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2001;7:568–575
  79. Shimoni A, Kroger N, Zander AR, et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003;17(2):290–297
  80. Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002;100(5):1590–1595
  81. DeAngelo DJ, Hochberg EP, Alyea EP, et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2004;10(15):5065–5071
  82. Waller EK, Boyer M. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells. Bone Marrow Transplantation. 2000;25(supplement 2):S20–S24
  83. Servida P, Rossini S, Traversari C, et al. Gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in a patient affected by EBV-induced lymphoma. Blood. 1993;82:214a
  84. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276(5319):1719–1724
  85. de Bueger M, Bakker A, Van Rood JJ, et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. Journal of Immunology (Baltimore, Md.: 1950). 1992;149(5):1788–1794
  86. Mutis T, Gillespie G, Schrama E, et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nature Medicine. 1999;5(7):839–842
  87. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nature Medicine. 2002;8(4):410–414
  88. Bonnet D, Warren EH, Greenberg PD, et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(15):8639–8644
  89. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 1998;91(6):2197–2207
  90. Alyea EP, Canning C, Neuberg D, et al. CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplantation. 2004;34(2):123–128
  91. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. [see comment]. Nature Medicine. 2003;9(9):1144–1150
  92. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. [see comment]. The New England Journal of Medicine. 2005;353(13):1321–1331
  93. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2973–2978
  94. Molldrem J. Vaccinating transplant recipients. Nature Medicine. 2005;11:1162–1163
  95. Rapoport A, Stadtmauer E, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nature Medicine. 2005;11:1230–1237
  96. Shiobara S, Nakao S, Ueda M, et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplantation. 2000;26(7):769–774
  97. Porter D, Antin J. Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. Leukemia & Lymphoma. 1995;17:191–197
  98. Depil S, Deconinck E, Milpied N, et al. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplantation. 2004;33(5):531–534
  99. van Rhee R, Savage D, Blackwell J, et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplantation. 1998;21:1055–1061

PII: S1521-6926(06)00035-1

doi: 10.1016/j.beha.2006.05.003

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 737-755 , December 2006

Article Tools

* Image Usage & Resolution